Curanex Pharmaceuticals Inc

Contributing Author

Recent Articles by Curanex Pharmaceuticals Inc

Apr-02	Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company's Evolution Into a Broader Therapeutics Development Company CURX GlobeNewswire
Mar-30	Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission CURX GlobeNewswire
Mar-18	Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission CURX +10.43% GlobeNewswire
Mar-12	Curanex Expands Scientific Advisory Board With Two Distinguished Researchers CURX -11.59% GlobeNewswire
Mar-11	Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board CURX +6.16% GlobeNewswire
Mar-05	Curanex Forms World Class Scientific Advisory Board CURX GlobeNewswire
Feb-25	Curanex Provides Operational Update on Key Regulatory Milestones CURX GlobeNewswire
Oct-22	Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement CURX +14.39% GlobeNewswire
Sep-12	Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters CURX GlobeNewswire
Aug-27	Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering CURX +15.92% CURX +11.37% GlobeNewswire
Aug-26	Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering CURX GlobeNewswire